Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Luspatercept effective for myelofibrosis-associated anaemia

Luspatercept effective for myelofibrosis-associated anaemia

Presented By
Prof. Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, USA
ASH 2019
Prof. Aaron Gerds (Cleveland Clinic Taussig Cancer Institute, USA) presented the preliminary results of an ongoing, open-label, phase 2 trial, which evaluated whether anaemia resulting from myelofibrosis (MF) could be effectively treated with erythroid maturation agent luspatercept [1]. In this ongoing trial, patients (n=74) with MF and anaemia received luspatercept at 21-day intervals. Based on their red blood cell transfusion-dependent status at baseline, patients were allocated to 4 cohorts, also taking into account whether or not they had been receiving treatment with ruxolitinib at the start of the study. Cohort 1 (n=20) included non-transfusion dependent (NTD) participants who had not received ruxolitinib treatment, and Cohort 2 (n=21) included transfusion-dependent (TD) participants, also without ruxolitinib. For patients who had received ruxolitinib, Cohort 3A (n=14) were NTD, and Cohort 3B patients (n=19) were TD. The primary endpoint was a...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on